Zimmer Biomet Holdings, Inc. (ZBH)
Automate Your Wheel Strategy on ZBH
With Tiblio's Option Bot, you can configure your own wheel strategy including ZBH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZBH
- Rev/Share 40.4392
- Book/Share 71.5422
- PB 1.2402
- Debt/Equity 0.5724
- CurrentRatio 3.2364
- ROIC 0.0472
- MktCap 17584649375.0
- FreeCF/Share 7.1878
- PFCF 12.3496
- PE 21.8299
- Debt/Assets 0.3454
- DivYield 0.0108
- ROE 0.0625
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ZBH | JP Morgan | Overweight | Neutral | -- | $100 | Nov. 6, 2025 |
| Initiation | ZBH | Rothschild & Co Redburn | -- | Buy | -- | $130 | Sept. 18, 2025 |
| Upgrade | ZBH | Roth Capital | Neutral | Buy | -- | $135 | July 15, 2025 |
| Upgrade | ZBH | JP Morgan | Neutral | Overweight | $125 | $128 | Dec. 17, 2024 |
| Initiation | ZBH | Wolfe Research | -- | Peer Perform | -- | -- | Sept. 10, 2024 |
News
Time To Buy Zimmer Biomet Stock?
Published: November 06, 2025 by: Forbes
Sentiment: Positive
Zimmer Biomet (ZBH) stock ought to be on your radar. Here's why – it is presently trading within the support range ($83.17 – $91.93), levels from which it has rebounded significantly in the past.
Read More
Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Zimmer Biomet's Q3 EPS beats expectations, but a revenue miss and trimmed outlook send shares sliding in pre-market trading.
Read More
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2025 Earnings Call Transcript
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Zimmer Biomet Holdings, Inc. ( ZBH ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants David DeMartino - Senior Vice President of Investor Relations Ivan Tornos - President, CEO & Chairman of the Board Suketu Upadhyay - CFO and Executive VP of Finance, Operations & Supply Chain Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - BofA Securities, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Patrick Wood - Morgan Stanley, Research Division Larry Biegelsen - Wells Fargo Securities, …
Read More
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
Company to Spotlight Comprehensive Hip & Knee Portfolios and Latest Advancements in Robotics, Including the mBôs™ System Following Recent Acquisition of Monogram Technologies WARSAW, Ind., Oct. 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting bold innovations across its broad robotics and musculoskeletal portfolio at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).
Read More
The Launch of Foot and Ankle Trauma Solutions May Boost ZBH Stock
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer Biomet expands its foot & ankle trauma lineup with Gorilla Pilon Fusion & Phantom TTC Trauma Nail launches.
Read More
Are Investors Undervaluing Zimmer Biomet (ZBH) Right Now?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2025 Financial Results
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
WARSAW, Ind. , Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m.
Read More
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The robotic surgery market is undergoing rapid transformation, driven by technological advancements, increasing adoption in hospitals, and a shift toward minimally invasive procedures. As of 2025, it's growing rapidly, focusing on precision, AI integration, and expanding its use across specialties like urology, gynecology, orthopedics, and general surgery.
Read More
All You Need to Know About Zimmer (ZBH) Rating Upgrade to Buy
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer (ZBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Is Zimmer Biomet (ZBH) Stock Undervalued Right Now?
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
ZBH or ESLOY: Which Is the Better Value Stock Right Now?
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Should You Add Zimmer Biomet Stock to Your Portfolio Now?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.
Read More
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
4 Stocks to Buy From a Top-Performing Fund Manager
Published: August 12, 2025 by: Morningstar
Sentiment: Positive
Bill Nygren's Oakmark Fund recently took new positions in these undervalued stocks.
Read More
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer Biomet gains as Q2 earnings and revenues top estimates; full-year EPS guidance raised on strong segment growth.
Read More
Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Zimmer Biomet to Report Q2 Earnings: Here's What to Expect
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.
Read More
Zimmer Biomet Q2 Preview: Combining Monogram Autonomous Robotics With ROSA
Published: July 21, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my Buy rating on Zimmer Biomet Holdings, Inc., setting a fair value of $133 per ZBH share due to strong business acceleration opportunities. The Monogram Technologies acquisition could significantly enhance Zimmer's knee robotics, positioning it to better compete with Stryker through advanced autonomous technology. Paragon 28's integration is on track and expected to boost Zimmer's foot and ankle portfolio, contributing to topline growth in a fast-expanding market.
Read More
Final Trades: Uber, Delta, Zimmer Holdings and Boeing
Published: July 11, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
Read More
We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos
Published: May 20, 2025 by: CNBC Television
Sentiment: Neutral
Ivan Tornos, Zimmer Biomet CEO, joins 'Closing Bell Overtime' from the CNBC CEO Council Summit to talk navigating a changing political landscape, partnering with Arnold Schwarzenegger and more.
Read More
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
Published: May 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.
Read More
About Zimmer Biomet Holdings, Inc. (ZBH)
- IPO Date 2001-07-25
- Website https://www.zimmerbiomet.com
- Industry Medical - Devices
- CEO Ivan Tornos
- Employees 17000